A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

Trial Details

NCT ID

NCT06952478

Phase

PHASE3

Sponsor

Celltrion

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

• CT-P44(Daratumumab)
• Darzalex Faspro(Daratumumab)

Locations (sample)

• Taipei, Beitou District, Taiwan|25.05306,121.52639

Key Eligibility Criteria

• Male or female with 18 years of age or older.
• Patient must have documented multiple myeloma (MM) according to IMWG criteria
• Patient must have a documented relapsed or refractory disease.
• Patient must have achieved a response (PR or better based on investigator's determination of response by the IMWG criteria) to at least one prior r…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.